Aprea Therapeutics, Inc. (APRE) company profile
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
About Aprea Therapeutics
Pharmaceutical Preparations, SIC 2834
Aprea Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to discovering and developing targeted therapies for patients with biomarker-defined cancers. Utilizing the concept of synthetic lethality, the company designs small molecule inhibitors that target specific cancer-related genetic alterations and DNA damage response pathways to selectively destroy cancer cells while sparing healthy tissue. Aprea Therapeutics focuses on advancing its core pipeline programs, which feature its clinical-stage WEE1 kinase inhibitor, APR-1051, and its oral macrocyclic ATR inhibitor, ATRN-119, alongside preclinical candidates such as the DYRK1 inhibitor APR-1602.
The company operates primarily through research, clinical development, and translational collaborations in the United States, conducting active clinical trials across multiple study sites nationwide. Aprea Therapeutics relies on third-party contract manufacturers for the synthesis of active pharmaceutical ingredients and clinical trial drug supplies. The provided text notes that Aprea Therapeutics AB originally incorporated in 2002 before a corporate reorganization established Aprea Therapeutics, Inc. as the parent entity, but does not disclose specific headquarters facilities or locations.
Summary of the business section of Aprea Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aprea Therapeutics, Inc.
- Founded
- 2002
- Headquarters
- Doylestown, PA
- Address
- 3805 Old Easton Road 18902
- Phone
- (215) 948-4119
- Website
- aprea.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- APRE
- Exchange
- Nasdaq
- IPO date
- Oct 4, 2019
- Shares outstanding
- 13M, Aug 12, 2026
- Public float
- $8.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Feb 13, 2023
- SEC CIK
- 1781983
- CUSIP
- 03836J201
- ISIN
- US03836J2015
- FIGI
- BBG00Q6Q3K37
- Share class FIGI
- BBG00Q6Q3KV6
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Oren Gilad | President/CEO, Director | 395,695 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 |
| Jean-Pierre Bizzari | Director | 4,180 |
| Bernd R. Seizinger | Director | 48,910 |
| Richard Peters | Director | 6,254 |
| Gabriela Gruia | Director | 4,180 |
| Rifat Pamukcu | Director | 22,689 |
| Michael Grissinger | Director | 6,024 |
| Marc Duey | Director | 259,892 |
| John B. Henneman Iii | Director | 13,364 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Oren Gilad President and Chief Executive Officer | $594.88K | $14.80K | $43.58K | $4.01K | $657.26K | -14% |
| John P. Hamill Chief Financial Officer | $454.27K | $7.40K | $21.81K | $7.17K | $490.65K | -9% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 4, 2019
- Offer price
- $15.00
- Securities offered
- 5,666,667
- Gross proceeds
- $85.00M
- Exchange
- Nasdaq
- First trading day
- Oct 3, 2019
- First-day close
- $20.50+36.7%
- Lock-up ends (est.)
- Mar 31, 2020
“The initial public offering price of our common stock is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 8 full-time employees, of which 5 employees are directly engaged in research and development with the rest providing administrative, business and operations support.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?